2026 ACCP Virtual Journal Club Webinar-April | Assessment of Hepatic Impairment and Implications for Pharmacokinetics of Substance Use Treatment - On Demand
-
You must log in to register
- User - Free!
- Member - Free!
2026 ACCP Virtual Journal Club Webinar: Assessment of Hepatic Impairment and Implications for Pharmacokinetics of Substance Use Treatment
Live Session: Wednesday, April 22nd, 2026, from 12:00 to 1:00 PM ET
On Demand: April 22nd, 2026 to April 22nd, 2029
Why is this webinar important to your practice?
Learners that complete this webinar will have enhanced knowledge of the impact of hepatic impairment on drug metabolism and pharmacokinetics. This activity reviews the pathophysiology of liver disease and its effects on hepatic drug clearance, along with current approaches to assessing hepatic function, including the Child-Pugh classification, MELD score and emerging noninvasive techniques. Emphasis is placed on how hepatic impairment contributes to variability in drug exposure and informs dose selection, with application to clinical pharmacology and medications used in patients with liver dysfunction. This activity is designed to enhance knowledge of hepatic function assessment, interpretation of pharmacokinetic changes and application of evidence-informed dosing strategies to optimize patient outcomes.
Target Audience:
Interprofessional team of Physicians, Pharmacists, PhDs and other health care professionals involved in clinical pharmacology and the care of patients with hepatic impairment.
Learning Objectives
After completing this activity, the learner will be able to:
- Describe the pathophysiologic mechanisms of hepatic impairment (e.g., fibrosis, cirrhosis, inflammation) and their impact on hepatic drug metabolism and transport;
- Discuss the challenges and limitations of the current scales and scoring system to assess hepatic impairment;
- Explain the impact of hepatic impairment on pharmacokinetic parameters, including drug clearance, protein binding, and hepatic extraction.
Andrew Talal
Professor of Medicine
University at Buffalo, State University of New York
Andrew Talal, MD, MPH is Professor of Medicine at SUNY, University at Buffalo, a physician-scientist, and board-certified gastroenterologist with >30 years evaluating liver drug metabolism and studying how to improve medication access among underserved populations. He recently completed a stepped wedge, randomized controlled trial of facilitated telemedicine for HCV treatment integrated into opioid treatment programs. The study resulted in a 2-fold improvement in HCV cure compared to offsite referral as described in a JAMA publication. The study received a 2025 Top 10 Clinical Research Achievement Award and one of three Distinguished Clinical Study awards by the Clinical Research Forum. Dr. Talal was appointed by the New York Governor to the New York State HCV Elimination Task Force, and he serves on the NYS HCV Guidelines committee. Dr. Talal has recently been appointed to the Center for Medicare and Medicaid Service’s Technical Expert Panel for Eligible Clinician Electronic Clinical Quality Measures Program.